China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Genentech, a biotechnology company that pledged last year to build a manufacturing facility in southern Wake County, said it ...

This session examines Saudi Arabia’s value proposition as a regional manufacturing hub for healthcare and medical ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...

VanEck Biotech ETF gets a Hold rating as top holdings face low growth, patent cliffs, and rich valuation vs. peers. Click to read my latest analysis of BBH.

The green shoots suggesting a comeback was in sight for biotech stocks last year have mostly grown into proverbial flowering plants—but one company’s precipitous year-over-year decline in market ...

The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

We all know someone waiting on a medical breakthrough. It could be a parent battling a chronic illness, a colleague pushing ...

Explore how leadership in biotech drives success through a milestone approach, aligning teams and culture from science to ...

Commentary: To win the biotech battle, we don’t need entirely new strategies. We just need to avoid self-destructive policies ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...